SEC Form 4 · accession 0001694665-19-000004
Evelo Biosciences, Inc. · EVLO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Simba Gill
Officer — President & CEO · Director
Period of report
Jan 14, 2019
Accepted (ET)
Jan 16, 2019 · 8:54 am EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001694665
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.71 | Jan 14, 2019 | A | 220,000 | A | — | Jan 14, 2029 | Common Stock | 220,000 | 220,000 | D |
Explanation of responses
- F1These options will vest as to 25% of the total grant on the first anniversary of the grant date with the remainder vesting in equal quarterly installments over a three-year period thereafter, subject to continued employment on such dates.